Advertisement

Topics

Celgene Corporation Company Profile

06:09 EST 20th January 2019 | BioPortfolio

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer and immunological diseases.Celgene's medical research and development team is working to extend the boundaries in the areas of small molecule immunotherapeutic and biocatalytic chiral chemistry by developing both new pharmaceuticals and chirally pure versions of existing drugs. Celgene's agrochemical unit, Celgro, is dedicated to the development of chirally pure crop protection agents.



Our goal is to provide hope and ease suffering through the discovery and development of products for therapies for patients with severe and difficult to treat diseases.

Location

86 Morris Avenue
Summit
NJ
07901
United States of America

Contact

Phone: 1-908-673-9000
Fax: 908 271 4184


News Articles [579 Associated News Articles listed on BioPortfolio]

wikifolio whispers p.m. zu Celgene, VISA, Apple ...

Celgene 34.37% speculatorius (MB01AWVG): Perfekt. Celgene wird wohl von Bristol-Myers aufgekauft. Gute Entscheidung vor ca. 1/2 Jahr Celgene gegenüber Gilead stärker zu gewichten. Auch Bristol-Myer....

NantCell completes second round, gets $30mm from Celgene

Oncology immunotherapy developer NantCell Inc. (a NantHealth company) raised $30mm through a crossover investment from Celgene. This is the second such round for NantCell and Celgene; NantCell was fou...

Celgene Doubles Down on Dragonfly, Pays $50M to Expand Cancer Pact

Celgene’s collaboration with Dragonfly Therapeutics is less than 18 months old, but the pharmaceutical company is already expanding the alliance. Celgene (NASDAQ: CELG) is paying Waltham, MA-based D...

Celgene's Ozanimod Versus Biogen's Avonex: Celgene Has the Edge

Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III...

Celgene-Aktie: Und plötzlich ging alles ganz schnell!

Wer hätte das gedacht, Celgene ist plötzlich zum Übernahmekandidaten geworden und soll nun im Konzern Bristol-Myers-Squibb aufgehen. BMS bietet 74 Mrd. USD für Celgene und liegt damit deutlich üb...

Aprinoia's tau PET tracer licensed to Celgene

A nonexclusive licensing agreement was signed by Aprinoia Therapeutics and Celgene to allow Celgene to use Aprinoia's early-s -More- 

Bristol-Myers Squibb acquires Celgene for $74bn, deepening strength in oncology

In the fourth-largest biopharma acquisition to date, Bristol-Myers Squibb Co. bought top-tier public biotech Celgene Corp. for $74bn. For each Celgene share, BMS will issue one of its shares (valued a...

Celgene-Aktie: Wie sind die Zahlen ausgefallen?

Am 26. Juli veröffentlichte Celgene seine Quartalszahlen und anschließend konnte der Kurs der Aktie auch etwas zulegen. Zu Beginn der neuen Woche zeigte sich die Celgene-Aktie ebenfalls stark. Habe....

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Artificial Intelligence and the Future of the Drug Safety Professional.

The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope wit...

Ozanimod for the treatment of relapsing remitting multiple sclerosis.

Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has ...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting...

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by ...

Companies [199 Associated Companies listed on BioPortfolio]

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

Celgene Cellular Therapeutics

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

Celgene Corporation

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer and immunological diseases.Celgene's medical research and devel...

Celgene Corporation and BeiGene, Ltd.

More Information about "Celgene Corporation" on BioPortfolio

We have published hundreds of Celgene Corporation news stories on BioPortfolio along with dozens of Celgene Corporation Clinical Trials and PubMed Articles about Celgene Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Corporation Companies in our database. You can also find out about relevant Celgene Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record